Clinical Characteristics of Toxicities of Immune Checkpoint Inhibitors and Their Impact on Efficacy in Solid Cancers: An Analysis of Real-World Data in Moroccan Patients
JCO Global Oncology,
Год журнала:
2025,
Номер
11
Опубликована: Фев. 1, 2025
PURPOSE
Patients
receiving
immune
checkpoint
inhibitors
(ICIs)
may
induce
immune-related
adverse
events
(irAEs).
This
study
aimed
to
evaluate
the
toxicity
induced
by
ICIs
and
explore
correlation
between
efficacy
in
a
Moroccan
population.
METHODS
We
conducted
prospective
of
patients
with
solid
tumors
who
received
pembrolizumab
or
atezolizumab
at
National
Institute
Oncology,
Rabat
from
July
2018
December
2023.
identified
irAEs
according
ASCO
2021
guidelines
graded
them
Common
Terminology
Criteria
for
Adverse
Events
Version
4.0.
Efficacy
respect
progression-free
survival
(PFS)
overall
(OS)
was
determined.
A
Cox
regression
model
used
determine
association
survival.
RESULTS
Eighty-six
were
included.
The
primary
tumor
types
lung
(40.7%),
skin
(29.1%),
GI
cancer
(14%).
most
commonly
included
(67.4%)
(32.6%).
as
monotherapy
(77.9%)
combination
(22.1%).
total
58
presented
any
kind
irAEs.
common
toxicities
both
groups
GI,
rates
25.3%
31.5%,
respectively.
showed
significantly
longer
median
PFS
compared
those
without
(9
v
3.6
months;
hazard
ratio
[HR],
0.5
[95%
CI,
0.32
0.99];
P
=
.04).
OS
than
but
not
statistically
significant
(19
10.3
HR,
0.8
0.39
1.7];
.5).
CONCLUSION
Our
results
indicated
that
have
potential
tumors.
These
effects
GI.
development
associated
improved
effectiveness
ICI
treatment
across
different
malignancies.
Язык: Английский
The efficacy of ICIs rechallenge in advanced small cell lung cancer after progression from ICIs plus chemotherapy: A real-world study
International Immunopharmacology,
Год журнала:
2025,
Номер
152, С. 114372 - 114372
Опубликована: Март 5, 2025
Язык: Английский
Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemia
Journal of Oncology Pharmacy Practice,
Год журнала:
2024,
Номер
30(6), С. 1101 - 1110
Опубликована: Апрель 5, 2024
Introduction
Acute
pancreatitis
(AP)
following
drug-induced
hypertriglyceridemia
is
a
rare
clinical
phenomenon.
Immune
checkpoint
inhibitors
have
revolutionized
treatment
for
variety
of
solid
organ
and
hematological
malignancies.
Pembrolizumab
programmed
cell
death
receptor-1
(PD-1)
inhibitor
that
has
shown
promising
responses
in
many
advanced
cancers.
However,
constellation
immune-related
adverse
events
also
been
described.
There
are
reports
pembrolizumab-induced
hypertriglyceridemia,
but
AP
as
result
this
side
effect
remains
an
exceedingly
sequela.
Case
report
We
delineate
case
patient
with
stage
IVB
non-small-cell
lung
cancer
who
developed
progressive
abdominal
pain
nausea
administration
pembrolizumab
four
months.
Laboratory
studies
revealed
increased
serum
lipase
triglyceride
levels
at
12,562
IU/L
16,901
mg/dL,
respectively.
The
diagnosis
was
made
based
on
the
revised
Atlanta
classification
criteria.
After
ruling
out
alternative
causes,
considered
likely
etiology
AP.
Management
outcome
transferred
to
medical
intensive
care
unit
close
monitoring.
Treatment
initiated
intravenous
fluids,
medications,
insulin
infusion.
her
remained
persistently
elevated,
necessitating
therapeutic
apheresis.
She
recovered
well
no
complications
after
Discussion
pembrolizumab-associated
clinicopathologic
entity.
Given
widespread
use
immune
inhibitors,
knowledge
such
crucial.
Evaluation
before
initiating
therapy
may
be
mandated,
especially
patients
metabolic
comorbidities.
Язык: Английский
Predictive markers of response to immune checkpoint inhibitor rechallenge in metastatic non-small cell lung cancer
Exploration of Targeted Anti-tumor Therapy,
Год журнала:
2024,
Номер
5(6), С. 1271 - 1288
Опубликована: Окт. 18, 2024
Aim:
The
present
study
aims
to
evaluate
the
efficacy
of
rechallenge
with
immune
checkpoint
inhibitors
(ICIs)
compared
chemotherapy
and
predictive
role
clinical
parameters
in
non-small
cell
lung
cancer
(NSCLC)
patients
who
were
rechallenged.
Methods:
included
113
metastatic
NSCLC
had
initially
responded
ICIs
platinum-based
chemotherapy,
either
combination
first
line
or
sequentially
second
line,
but
later
experienced
disease
progression.
Of
those
patients,
52
received
ICI
61
exposed
chemotherapy.
Results:
In
cohort,
median
age
was
67
years,
38
men
(73.1%),
26
(50.0%)
squamous
carcinoma.
Patients
underwent
longer
overall
survival
(OS)
(12.9
months
vs.
9.6
months,
P
=
0.008).
Multivariate
analysis
for
progression-free
(PFS)
OS
revealed
that
poor
Eastern
Cooperative
Oncology
Group
Performance
Status
(ECOG
PS;
PFS:
0.013
OS:
0.037),
absence
objective
response
during
initial
therapy
(PFS:
0.014
0.028),
baseline
neutrophil-to-lymphocyte
ratio
(NLR)
≥
3.8
0.001
0.003)
negative
factors
rechallenge.
three
a
risk
model
named
as
NEO
score,
which
stratified
into
two
groups.
ECOG
PS
0-1,
treatment,
NLR
<
(favorable
group)
PFS
(8.6
3.0
0.001)
(16.6
5.5
all
markers
(poor
group).
There
no
association
between
score
outcomes
did
not
undergo
Conclusions:
showed
benefit,
particularly
3.8,
good
PS,
response.
Язык: Английский
TClC effectively suppresses the growth and metastasis of NSCLC via polypharmacology
Bioactive Materials,
Год журнала:
2024,
Номер
45, С. 567 - 583
Опубликована: Дек. 13, 2024
Язык: Английский
Re-Treatment With Immune Checkpoint Inhibitors
Canadian Journal of Health Technologies,
Год журнала:
2024,
Номер
4(7)
Опубликована: Июль 23, 2024
We
did
not
find
any
evidence
regarding
the
clinical
effectiveness
and
safety
of
second
re-treatment
with
pembrolizumab
for
non–small
cell
lung
cancer,
classical
Hodgkin
lymphoma,
advanced
melanoma.
cemiplimab
cutaneous
squamous
carcinoma.
evidence-based
guidelines
immune
checkpoint
inhibitors
melanoma,
Язык: Английский
Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta‐Analysis
Cancer Medicine,
Год журнала:
2024,
Номер
13(20)
Опубликована: Окт. 1, 2024
ABSTRACT
Background
Immune
checkpoint
inhibitors
(ICIs)
have
drastically
shifted
the
current
landscape
toward
a
wide
variety
of
malignancies.
However,
ICIs
are
interrupted
owing
immune‐related
adverse
events
(irAEs),
therapy
completion,
and
disease
progression.
The
risk–benefit
rechallenged
remains
inconclusive.
Herein,
systematic
review
meta‐analysis
were
conducted
to
evaluate
safety
efficacy
ICI
rechallenge
in
treatment
advanced
solid
tumor.
Methods
PubMed,
Web
Science,
Embase,
Cochrane
Library
searched
analyze
rechallenge.
study
protocol
was
approved
by
PROSPERO
International
Register
Systematic
Reviews
(CRD42022372222).
last
updated
search
date
March
2,
2024.
Objective
response
rate
(ORR),
control
(DCR),
overall
survival
(OS),
incidence
rates
all‐
high‐grade
irAEs
evaluated.
Results
A
total
41
retrospective
studies
comprising
2343
patients
ultimately
enrolled
for
qualitative
quantitative
assessments.
1200
(51.2%)
individuals
male
median
age
66
years
(range
18–97
years).
majority
tumors
lung
cancer
(
n
=
898,
38.3%).
occurrence
all‐grade
(grade
3
or
4)
between
initial
readministration
not
significantly
different
(all‐grade:
OR,
0.75,
95%
CI:
0.39–1.45,
p
0.40;
I
2
87%;
high‐grade:
0.96,
0.62–1.49,
0.87,
65%).
restart
presented
decreased
ORR
DCR
compared
administration
(ORR:
0.36,
0.23–0.56,
<
0.00001;
67%;
DCR:
0.62,
0.43–0.89,
0.010;
53%).
Seven
with
513
analysis
revealed
nonsignificant
difference
OS
discontinuation
cohorts
(hazard
ratio
[HR]:
0.68,
confidence
interval
(CI):
0.35
1.35,
0.27).
Conclusion
Rechallenging
immunotherapy
is
feasible,
should
be
carefully
evaluated
multidisciplinary
team
prior
close
monitoring
assessment
ratio.
Therefore,
prospective
trials
essential
guide
clinicians
decision‐making
process.
Registration:
CRD42022372222.
Язык: Английский